At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Regadenosondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging
In Brief
A Phase 4 clinical trial evaluating Regadenoson for Coronary Artery Disease. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to measure the changes in cardiac function during a Lexiscan pharmacologic stress test using cardiac magnetic resonance imaging test.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartSep 2014
Primary CompletionJan 2018
Study CompletionMar 2018
TodayJul 2026
First PostedApr 16, 2014
Enrollment StartSep 3, 2014
Primary CompletionJan 16, 2018
Study CompletionMar 23, 2018
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.2 years ago
Interventions
Regadenosondrug
Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.